United States. Securities and Exchange Commission
Xcel Energy's subsidiary, Southwestern Public Service Company (SPS), filed an electric rate case with the Public Utility Commission of Texas (PUCT) in February 2023, seeking a base rate revenue increase of $149 million, which would result in a 13% impact on customer bills. In March 2023, SPS updated
United States. Securities and Exchange Commission
On August 8, 2023, PayPal Holdings, Inc. announced the departure of Jonathan Auerbach, Executive Vice President, Chief Strategy, Growth and Data Officer, effective June 1, 2024. Auerbach will continue to serve in his current role until December 31, 2023, after which he will remain with the company as an advisor
United States. Securities and Exchange Commission
RegeneRx Biopharmaceuticals, Inc. has announced that it has received consents from the holders of 51.07% of the company's common stock in favor of a proposed reverse stock split, which will allow the company to suspend its public reporting obligations under the Securities Exchange Act of 1934. The
United States. Securities and Exchange Commission
Enstar Group LTD, a Bermuda-based global specialty insurance group, has recently filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) announcing its entry into a materially definitive agreement. The company, together with its subsidiaries, has entered into a $800 million amended and restated letter of credit
United States. Securities and Exchange Commission
At the 2023 annual meeting of BioLife Solutions Inc., held on July 21, 2023, the company's stockholders voted in favor of several key proposals, including the re-election of seven directors and the approval of the compensation of the company's named executive officers. The meeting also saw
United States. Securities and Exchange Commission
The Securities and Exchange Commission has adopted new rules requiring public companies to disclose within four days any cybersecurity breaches that could affect their bottom lines. This move aims to protect investors by providing transparency into what can be an "opaque but growing risk." Delays in disclosure will
United States. Securities and Exchange Commission
Coherus BioSciences, Inc. has filed a Current Report with the U.S. Securities and Exchange Commission announcing the appointment of Michael Ryan, Pharm.D., to its Board of Directors. Dr. Ryan brings over four decades of experience in academia and the biopharmaceutical industry, having served in various leadership roles, including
United States. Securities and Exchange Commission
Pieris Pharmaceuticals, Inc. has filed a Current Report with the U.S. Securities and Exchange Commission, announcing the termination of its License and Collaboration Agreement with AstraZeneca AB, effective October 15, 2023. This development comes after AstraZeneca provided a written notice of termination on July 17, 2023, citing non-clinical safety
United States. Securities and Exchange Commission
Alliant Energy Corporation has filed a Form 8-K with the U.S. Securities and Exchange Commission announcing the appointment of Ignacio A. Cortina as a new member of the Boards of Directors of Alliant Energy Corporation, Interstate Power and Light Company, and Wisconsin Power and Light Company, effective July 14,
United States. Securities and Exchange Commission
Alliant Energy Corporation, alongside its subsidiaries Interstate Power and Light Company and Wisconsin Power and Light Company, has appointed Ignacio A. Cortina as a member of their Boards of Directors. This appointment took place on July 14, 2023, with Cortina set to stand for election at the Alliant Energy 2024
United States. Securities and Exchange Commission
Caribou Biosciences, Inc., a biotechnology company developing novel cell therapies, has secured $25 million in financing from Pfizer Inc. through a private placement transaction. The deal represents a significant milestone for Caribou Biosciences, allowing the company to further develop its allogeneic anti-BCMA CAR-T cell therapy, CB-011. The private placement agreement
United States. Securities and Exchange Commission
Mallinckrodt plc, a global biopharmaceutical company, has engaged in discussions with stakeholders, including parties holding substantial positions across its capital structure and representatives of the Opioid Master Disbursement Trust II. The company is actively evaluating its capital needs in light of its obligations under its opioid settlement and long-term debt,
